Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Arentz

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Drug Discovery Today. Disease Mechanisms|August 5, 2008
Tuberculosis Infection: Insight from ImmunogenomicsMatthew Arentz, Thomas R Hawn
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2005
Vomiting and rapid weight loss in a man with newly diagnosed HIV infectionMatthew Arentz, Beth Kirkpatrick, Alicia Casey
The Lancet. Digital Health|February 24, 2023
AI-CAD for tuberculosis and other global high-burden diseasesMatthew Arentz, Nikhil Jagtiani, Sandra Kik, et al.
Plos One|October 8, 2013
Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant tuberculosisMatthew Arentz, Bess Sorensen, David J Horne, et al.
BMC Infectious Diseases|January 28, 2022
The impact of the COVID-19 pandemic and associated suppression measures on the burden of tuberculosis in IndiaMatthew Arentz, Jianing Ma, Peng Zheng, et al.
Plos One|November 13, 2012
Association between smoking and latent tuberculosis in the U.S. population: an analysis of the National Health and Nutrition Examination SurveyDavid J Horne, Monica Campo, Justin R Ortiz, et al.
Radiology. Artificial Intelligence|January 10, 2024
AI for Detection of Tuberculosis: Implications for Global HealthEui Jin Hwang, Won Gi Jeong, Pierre-Marie David, et al.
Journal of Clinical Microbiology|November 16, 2012
Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugsDavid J Horne, Lancelot M Pinto, Matthew Arentz, et al.
Plos One|November 13, 2012
Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic reviewMatthew Arentz, Patricia Pavlinac, Michael E Kimerling, et al.
PLOS Digital Health|January 23, 2025
A comparison of CXR-CAD software to radiologists in identifying COVID-19 in individuals evaluated for Sars CoV-2 infection in Malawi and ZambiaSam Linsen, Aurélie Kamoun, Andrews Gunda, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Drug Discovery Today. Disease Mechanisms|August 5, 2008
Tuberculosis Infection: Insight from ImmunogenomicsMatthew Arentz, Thomas R Hawn
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2005
Vomiting and rapid weight loss in a man with newly diagnosed HIV infectionMatthew Arentz, Beth Kirkpatrick, Alicia Casey
The Lancet. Digital Health|February 24, 2023
AI-CAD for tuberculosis and other global high-burden diseasesMatthew Arentz, Nikhil Jagtiani, Sandra Kik, et al.
Plos One|October 8, 2013
Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant tuberculosisMatthew Arentz, Bess Sorensen, David J Horne, et al.
BMC Infectious Diseases|January 28, 2022
The impact of the COVID-19 pandemic and associated suppression measures on the burden of tuberculosis in IndiaMatthew Arentz, Jianing Ma, Peng Zheng, et al.
Plos One|November 13, 2012
Association between smoking and latent tuberculosis in the U.S. population: an analysis of the National Health and Nutrition Examination SurveyDavid J Horne, Monica Campo, Justin R Ortiz, et al.
Radiology. Artificial Intelligence|January 10, 2024
AI for Detection of Tuberculosis: Implications for Global HealthEui Jin Hwang, Won Gi Jeong, Pierre-Marie David, et al.
Journal of Clinical Microbiology|November 16, 2012
Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugsDavid J Horne, Lancelot M Pinto, Matthew Arentz, et al.
Plos One|November 13, 2012
Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic reviewMatthew Arentz, Patricia Pavlinac, Michael E Kimerling, et al.
PLOS Digital Health|January 23, 2025
A comparison of CXR-CAD software to radiologists in identifying COVID-19 in individuals evaluated for Sars CoV-2 infection in Malawi and ZambiaSam Linsen, Aurélie Kamoun, Andrews Gunda, et al.
Pageof 2